Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 7 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Aquestive Therapeutics, Inc. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 distinct examiners and 7 distinct art units, indicating that most cases are proceeding through separate examiner and art-unit combinations.
SCHLIENTZ, NATHAN W is the busiest examiner, with 2 pending matters. That limited concentration may support a focused review of the two matters assigned to this examiner, while the remaining docket requires more individualized preparation. Counsel can coordinate positions on pharmaceutical and biotechnology claim scope, but should validate each case against its particular art-unit practice and cited references.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (12%) |
| Double-patenting + other | 4 (50%) |
| Multi-statute (no §101) | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, NATHAN W | 2 | 41.3% | -18.8% |
| REYES, REGINALD R | 1 | 40.9% | +31.5% |
| KRINOS, EMILY LYNN | 1 | — | — |
| JOSEPH, JANET | 1 | 40.0% | +51.3% |
| LIPPERT, JOHN WILLIAM | 1 | 59.2% | +39.9% |
| KIM, DANIELLE A | 1 | 36.6% | +51.9% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17971282 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY PROFILES | LIPPERT, JOHN WILLIAM | 24d overdue |
| 17691107 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | KIM, DANIELLE A | 5d overdue |
| 17576923 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | SEAMAN, D MARGARET M | 19d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17971282 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY PROFILES | LIPPERT, JOHN WILLIAM | 24d overdue |
| 17691107 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | KIM, DANIELLE A | 5d overdue |
| 19191089 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | REYES, REGINALD R | — |
| 18334986 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | JOSEPH, JANET | — |
| Art Unit | Apps |
|---|---|
| 1616 | 2 |
| 3684 | 1 |
| 1614 | 1 |
| 1611 | 1 |
| 1615 | 1 |
| 1613 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19191089 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | REYES, REGINALD R | 3684 | DP | Non-Final OA | — | Pending | Apr 28, 2025 |
| 19074199 | TOPICAL DELIVERY OF EPINEPHRINE AND PRODRUG COMPOSITIONS | KRINOS, EMILY LYNN | 1614 | §102§103§112DP | Non-Final OA | — | Pending | Mar 07, 2025 |
| 18413556 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | SCHLIENTZ, NATHAN W | 1616 | §102DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18334986 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | JOSEPH, JANET | 1611 | §102§103§112DP | Non-Final OA | — | Pending | Jun 14, 2023 |
| 17971282 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY PROFILES | LIPPERT, JOHN WILLIAM | 1615 | §103§112 | Final Rejection | 24d overdue | Pending | Oct 21, 2022 |
| 17691107 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | KIM, DANIELLE A | 1613 | §103§112 | Non-Final OA | 5d overdue | Pending | Mar 09, 2022 |
| 17576923 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | SEAMAN, D MARGARET M | 1625 | §103§112 | Non-Final OA | 19d | Pending | Jan 15, 2022 |
| 17549219 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | SCHLIENTZ, NATHAN W | 1616 | §102§103DP | Non-Final OA | — | Pending | Dec 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAquestive Therapeutics, Inc. has 8 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Nathan W Schlientz has the most, with 2 of Aquestive Therapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
